

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Cite if Known

Application Number	09/815,330
Filing Date	March 23, 2001
First Named Inventor	John A. ZAIA et al
Group Art Unit	1648
Examiner Name	Laurie A. Scheiner
Attorney Docket Number	1954-333

TECH CENTER 1600/2000

DEC 12 2002

RECEIVED

Sheet 1 of 1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
LO	62	BENMOHAMED, LBACHIR et al., "Induction of CTL Response by a Minimal Epitope Vaccine in HLA A*0201/DR1 Transgenic Mice: Dependence on HLA Class II Restricted T _H Response," <i>Hum. Immunol.</i> 61:764-79, 2000.	
	63	BENINGA, J. et al., "Comparative Analysis of Fourteen Individual Human Cytomegalovirus Proteins for Helper T Cell Response," <i>Journal of General Virology</i> 76:153-160, 1995.	
	64	BOPPANA, SURESH B. et al., "Recognition of Human Cytomegalovirus Gene Products by HCMV-Specific Cytotoxic T Cells," <i>Virology</i> 222, (Article No. 0424): 293-296, 1996.	
	65	CHEE, M.S. et al., "Analysis of the Protein-Coding Content of the Sequence of Human Cytomegalovirus Strain AD169," <i>Current Topics in Microbiology and Immunology</i> 154: 125-169, 1990.	
	66	GREFFE, J.M. et al., "Cytomegalovirus Antigenemia Assay: Identification of the Viral Antigen as the Lower Matrix Protein PP65," <i>The Journal of Infectious Diseases</i> 166: 683-4, 1992.	
	67	LOLLI, FRANCESCO et al., "T and B Cell Responses to Cytomegalovirus Antigens in Healthy Blood Donors and Bone Marrow Transplant Recipients," <i>FEMS Immunol. Med. Microbiol</i> 7: 55-62, 1993.	
	68	MICHELSON, S. et al., "Properties of a Human Cytomegalovirus-Induced Protein Kinase," <i>Virology</i> 134: 259-268, 1984.	
	69	PLOTKIN, STANLEY A., "Cytomegalovirus Vaccine," <i>Am Heart J.</i> 138 (No. 5, Part 2): S484-S487, 1999.	
	70	OHLIN, MATA et al., "Human Antibody Reactivity Against the Lower Matrix Protein (pp65) Produced by Cytomegalovirus," <i>Clin. Diagn Lab. Immunol.</i> 2(3): 325-329, 1995.	
	71	SHIRAI, MUTSUNORI et al., "CTL Responses of HLA-A2.1-Transgenic Mice Specific for Hepatitis C Viral Peptides Predict Epitopes for CTL of Humans Carrying HLA-A2.1," <i>The Journal of Immunology</i> 154: 2733-2742, 1995.	
	72	SOLACHE, ALEJANDRA et al., "Identification of Three HLA-A*0201-Restricted Cytotoxic T Cell Epitopes in the Cytomegalovirus Protein pp65 That Are Conserved Between Eight Strains of the Virus," <i>The Journal of Immunology</i> 163: 5512-5518, 1999.	
	73	SOMOGYI, TERESA et al., "Genomic Location of a Human Cytomegalovirus Protein with Protein Kinase Activity (PK68)," <i>Virology</i> 174: 276-285, 1990.	
	74	SUN, QI et al., "B Lymphoblastoid Cell Lines as Efficient APC to Elicit CD8 ⁺ T Cell Responses Against a Cytomegalovirus Antigen ¹ ," <i>The Journal of Immunology</i> 165: 4105-4111, 2000.	
	75	WENTWORTH, PEGGY A. et al., "Identification of A2-Restricted Hepatitis C Virus-Specific Cytotoxic T Lymphocyte Epitopes from Conserved Regions of the Viral Genome," <i>Int. Immunol.</i> 8 (5): 651-659, 1996.	
	76	YAO, ZHI-QIANG et al., "Site-Directed Mutation in a Conserved Kinase Domain of Human Cytomegalovirus-pp65 with Preservation of Cytotoxic T Lymphocyte Targeting," <i>Vaccine</i> 19: 1628-1635, 2001.	
	77	ZAIS, JOHN A. et al., "Infrequent Occurrence of Natural Mutations in the pp65 ₄₉₅₋₅₀₃ : Epitope Sequence Presented by the HLA A*0201 Allele Among Human Cytomegalovirus Isolates," <i>J. Virol.</i> 75 (5): 2472-2474, 2001.	

Examiner Signature

Date Considered

1/7/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹Unique citation designation number. *Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	09/815,330
				Filing Date	March 23, 2001
				First Named Inventor	John A. ZAIA, et al.
				Group Art Unit	1640 1648
				Examiner Name	Unassigned
Sheet	1	of	6	Attorney Docket Number	1954-333

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
	1	6,156,317		Diamond et al.	Dec. 5, 2000
	2	6,074,645		Diamond et al.	Jun. 13, 2000
	3	4,058,598		Stern et al.	Nov. 15, 1977
	4	5,248,768		Lussenhop et al.	Sep. 28, 1993
	5	5,180,813		Stinski	Jan. 19, 1993
	6	5,075,213		Pande et al.	Dec. 24, 1991
	7	4,762,780		Spector et al.	Aug. 9, 1988
	8	4,716,104		Harris et al.	Dec. 29, 1987
	9	4,698,225		Pereira	Aug. 25, 1987
	10	3,959,466		Plotkin	May 25, 1976

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee of Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number	Kind Code (if known)			



Examiner Signature	<i>[Signature]</i>	Date Considered	11/7/02
-----------------------	--------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	09/815,330
				Filing Date	March 23, 2001
				First Named Inventor	John A. ZAIA et al.
				Group Art Unit	1646 1648
				Examiner Name	Unassigned
Sheet	2	of	6	Attorney Docket Number	1954-333

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶		
	11	Pande, H., et al., "Structural Analysis of a 64-kDa Major Structural Protein of Human Cytomegalovirus (Towne): Identification of a Phosphorylation Site and Comparison to pp65 of HCMV (AD169)," <u>Virology</u> , Vol. 178, pp. 6-14, 1980.			
	12	Meyers, J.D., et al., "Risk Factors for Cytomegalovirus Infection After Human Marrow Transplantation," <u>The Journal of Infectious Diseases</u> , Vol. 153, No. 3, pp. 478-488, March 1986.			
	13	Quinnan, G.V., Jr., et al., "Cytotoxic T Cells in Cytomegalovirus Infection; HLA-Restricted T-Lymphocyte and Non-T-Lymphocyte Cytotoxic Responses Correlate with Recovery from Cytomegalovirus Infection in Bone-Marrow-Transplant Recipients," <u>The New England Journal of Medicine</u> , Vol. 307, No. 1, July 1, 1982, pp. 7-13.			
	14	Pande, H., et al., "Human Cytomegalovirus Strain Towne pp65 Gene: Nucleotide Sequence and Expression in <i>Escherichia coli</i> ," <u>Virology</u> , Vol. 182, pp. 220-228, 1991.			
	15	McLaughlin-Taylor, E., et al., "Identification of the Major Late Human Cytomegalovirus Matrix Protein pp65 as a Target Antigen for CD8+ Virus-Specific Cytotoxic T Lymphocytes," <u>Journal of Medical Virology</u> , Vol. 43, pp. 103-110, 1994.			
	16	Walter, E.A., et al., "Reconstitution of Cellular Immunity Against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor," <u>The New England Journal of Medicine</u> , pp. 1038-1044, October 19, 1995, Vol. 333, No. 16.			
	17	Borysiewicz, L.K., et al., "Human cytomegalovirus-specific cytotoxic T lymphocytes: requirements for <i>in vitro</i> generation and specificity," <u>Eur. J. Immunol.</u> , Vol. 13, pp. 804-809, 1983.			
	18	Zhou, Y.F., et al., "Association Between Prior Cytomegalovirus Infection and the Risk of Restenosis After Coronary Atherectomy," <u>The New England Journal of Medicine</u> , pp. 624-630 August 29, 1996.			
	19	Speir, Edith, et al., "Potential Role of Human Cytomegalovirus and p53 Interaction in Coronary Restenosis," <u>Science</u> , Vol. 265, pp. 391-394, July 15, 1994.			
	20	Li, C.-R., et al., "Recovery of HLA-Restricted Cytomegalovirus (CMV)-Specific T-Cell Responses After Allogeneic Bone Marrow Transplant: Correlation with CMV Disease and Effect of Ganciclovir Prophylaxis," <u>Blood</u> , Vol. 83, No. 7, pp. 1971-1979, April 1, 1994.			
	Examiner Signature			Date Considered	11/7/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.
1954-333.14a

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	09/815,330
				Filing Date	March 23, 2001
				First Named Inventor	John A. ZAIA et al.
				Group Art Unit	1646 1648
				Examiner Name	Unassigned
Sheet	3	of	6	Attorney Docket Number	1954-333



OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
	21	Goodrich, J.M., et al., "Early Treatment with Ganciclovir to Prevent Cytomegalovirus Disease After Allogeneic Bone Marrow Transplantation," <u>The New England Journal of Medicine</u> , Vol. 325, No. 23, pp. 1601-1607, Dec. 5, 1991.	
	22	Reusser, P., et al., "Cytotoxic T-Lymphocyte Response to Cytomegalovirus After Human Allogeneic Bone Marrow Transplantation: Pattern of Recovery and Correlation With Cytomegalovirus Infection and Disease," <u>Blood</u> , Vol. 78, No. 5, pp. 1373-1380, September 1, 1991.	
	23	Wills, M.R., et al., "The Human Cytotoxic T-Lymphocyte (CTL) Response to Cytomegalovirus Is Dominated by Structural Protein pp65: Frequency, Specificity, and T-Cell Receptor Usage of pp65-Specific CTL," <u>Journal of Virology</u> , pp. 7569-7579, November 1996.	
	24	Gilbert, M.J., et al., "Selective Interference with Class I major Histocompatibility Complex Presentation of the Major Immediate-Early Protein following Infection with Human Cytomegalovirus," <u>Journal of Virology</u> , pp. 3461-3469, June 1993, Vol. 67, No. 6.	
	25	Goodrich, J.M., et al., "Ganciclovir Prophylaxis To Prevent Cytomegalovirus Disease After Allogeneic Marrow Transplant," <u>Annals of Internal Medicine</u> , Vol. 118, pp. 173-178, 1993.	
	26	Schmidt, G.M., et al., "A Randomized, Controlled Trial of Prophylactic Ganciclovir for Cytomegalovirus Pulmonary Infection in Recipients of Allogeneic Bone Marrow Transplants," <u>The New England Journal of Medicine</u> , Vol. 324, No. 15, pp. 1005-1011, April 11, 1991.	
	27	Rasmussen, L., "Immune Response to Human Cytomegalovirus Infection," <u>Current Topics in Microbiology and Immunology</u> , Vol. 154, pp. 221-255, 1990.	
	28	Forman, S.J., et al., "A 64,000 Dalton Matrix Protein of Human Cytomegalovirus Induces in Vitro Immune Responses Similar to Those of Whole Viral Antigen," <u>The Journal of Immunology</u> , Vol. 134, No. 5, pp. 3391-3395, May 1985.	
	29	Borysiewicz, L.K., et al., "Human Cytomegalovirus-Specific Cytotoxic T Cells - Relative Frequency of Stage-specific CTL Recognizing the 72kD Immediate Early Protein and Glycoprotein B Expressed by Recombinant Vaccinia Viruses," <u>J. Exp. Med.</u> , Vol. 168, pp. 919-931, September 1988.	
	30	Diamond, D.J., et al., "Development of A Candidate HLA A*0201 Restricted Peptide-Based Vaccine Against Human Cytomegalovirus Infection," <u>Blood</u> , Vol. 90, No. 5, pp. 1751-1767, September 1, 1997.	

Examiner Signature		Date Considered	11/7/02
-----------------------	---	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.
1954-333.14b


INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	09/815,330
				Filing Date	March 23, 2001
				First Named Inventor	John A. ZAIA et al.
				Group Art Unit	1646 1648
				Examiner Name	Unassigned
Sheet	4	of	6	Attorney Docket Number	1954-333
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ⁶
	31	Winston, D.J., et al., "Ganciclovir Prophylaxis of Cytomegalovirus Infection and Disease in Allogeneic Bone Marrow Transplant Recipients - Results of a Placebo-Controlled, Double-Blind Trial," <u>Annals of Internal Medicine</u> , Vol. 118, pp. 179-184, 1993.			
	32	Greenberg, P.D., et al., "Development of a Treatment Regimen for Human Cytomegalovirus (CMV) Infection in Bone Marrow Transplantation Recipients by Adoptive Transfer of Donor-Derived CMV-Specific T Cell Clones Expanded <i>In Vitro</i> ," <u>Annals New York Academy of Sciences</u> , Vol. 636, pp. 184-195, 1991.			
	33	Ohlin, M., et al., "Characterization of human monoclonal antibodies directed against the pp65-kD matrix antigen of human cytomegalovirus," <u>Clin. Exp. Immunol.</u> , Vol. 84, pp. 508-514, 1991.			
	34	Rüger, B., et al., "Primary Structure and Transcription of the Genes Coding for the Two Virion Phosphoproteins pp65 and pp71 of Human Cytomegalovirus," <u>Journal of Virology</u> , pp. 446-453, Feb. 1987, Vol. 61, No. 2.			
	35	Boppana, S.B., et al., "Recognition of Human Cytomegalovirus Gene Products by HCMV-Specific Cytotoxic T Cells," <u>Virology</u> , Vol. 222, pp. 293-296, 1996.			
	36	Irmiere, A., et al., "Isolation and Characterization of a Noninfectious Virion-like Particle Released from Cells Infected with Human Strains of Cytomegalovirus," <u>Virology</u> , Vol. 130, pp. 118-133, 1983.			
	37	Retière, C., et al., "Generation of Cytomegalovirus-Specific Human T-Lymphocyte Clones by Using Autologous B-Lymphoblastoid Cells with Stable Expression of pp65 or IE1 Proteins: a Tool To Study the Fine Specificity of the Antiviral Response," <u>Journal of Virology</u> , pp. 3948-3952, May 2000, Vol. 74, No. 9.			
	38	Kern, Fl., et al., "Target Structures of the CD8+-T-Cell Response to Human Cytomegalovirus: the 72-Kilodalton Major Immediate-Early Protein Revisited," <u>Journal of Virology</u> , pp. 8179-8184, October 1999, Vol. 73, No. 10.			
	39	Gyulai, Z., et al., "Cytotoxic T Lymphocyte (CTL) Responses to Human Cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in Healthy Individuals: Reevaluation of Prevalence of IE1 Specific CTLs," <u>The Journal of Infectious Diseases</u> , Vol. 181, pp. 1537-1546, 2000.			
Examiner Signature				Date Considered	11/7/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	09/815,330
				Filing Date	March 23, 2001
				First Named Inventor	John A. ZAIA, et al.
				Group Art Unit	1646 1648
				Examiner Name	Unassigned
Sheet	5	of	6	Attorney Docket Number	1954-333

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
	40	Periera. L., et al., "Monoclonal Antibodies to Human Cytomegalovirus: Three Surface Membrane Proteins with Unique Immunological and Electrophoretic Properties Specify Cross-Reactive Determinants," <u>Infection and Immunity</u> , pp. 924-932, June 1982, Vol. 36, No. 3.	
	41	Gibson, W., et al., "Selection of Particles and Proteins for Use as Human Cytomegalovirus Subunit Vaccines, in "CMV: Pathogenesis and Prevention of Human Infection," March of Dimes Birth Defects Foundation, <u>Birth Defects: Original Article Series</u> , Vol. 20, No. 1, pp. 305-324, 1984.	
	42	Gönczöl, E., et al., "Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate," <u>Vaccine</u> , Vol. 13, No. 12, 1995, pp. 1080-1085.	
	43	Khattab, B. A.-M., "Three T-Cell Epitopes Within the C-Terminal 265 Amino Acids of the Matrix Protein pp65 of Human Cytomegalovirus Recognized by Human Lymphocytes," <u>Journal of Medical Virology</u> , Vol. 52, pp. 68-76, 1997.	
	44	Plotkin, S. A., et al., "Vaccines for the Prevention of Human Cytomegalovirus Infection," <u>Reviews of Infectious Diseases</u> , Vol. 12, Supplement 7, pp. S827-S838, September-October 1990.	
	45	Plotkin, S. A., et al., "Effect of Towne Live Virus Vaccine on Cytomegalovirus Disease after Renal Transplant," <u>Annals of Internal Medicine</u> , Vol. 114, No. 7, pp. 525-531, April 1, 1991.	
	46	Gibson, W., "Structural and Nonstructural Proteins of Strain Colburn Cytomegalovirus," <u>Virology</u> , Vol. 111, pp. 516-537, 1981.	
	47	Plotkin, S. A., et al., "Protective Effects of Towne Cytomegalovirus Vaccine Against Low-Passage Cytomegalovirus Administered as a Challenge," <u>The Journal of Infectious Diseases</u> , Vol. 159, No. 5, pp. 860-865, May 1989.	
	48	Gönczöl, E., et al., "Humoral Immune Response to Cytomegalovirus Towne Vaccine Strain and to Toledo Low-Passage Strain," <u>The Journal of Infectious Diseases</u> , Vol. 159, No. 5, pp. 851-859, May 1989.	
	49	Pande, H., et al., "Genomic Localization of the Gene Encoding a 32-kDa Capsid Protein of Human Cytomegalovirus," <u>Virology</u> , Vol. 167, pp. 306-310, 1988.	
	50	Stinski, M. F., et al., "Organization and Expression of the Immediate Early Genes of Human Cytomegalovirus," <u>Journal of Virology</u> , Vol. 46, No. 1, pp. 1-14, April 1983.	
Examiner Signature			Date Considered 11/7/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	09/815,330
				Filing Date	March 23, 2001
				First Named Inventor	John A. ZAIA et al.
				Group Art Unit	1646 1648
				Examiner Name	Unassigned
Sheet	6	of	6	Attorney Docket Number	1954-333
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ⁶
	51	Roby, C., et al., "Characterization of Phosphoproteins and Protein Kinase Activity of Virions, Noninfectious Enveloped Particles, and Dense Bodies of Human Cytomegalovirus," <u>Journal of Virology</u> , Vol. 59, No. 3, pp. 714-727, September 1986.			
	52	DeVal, M., et al., "Protection against Lethal Cytomegalovirus Infection by a Recombinant Vaccine Containing a Single Nonameric T-Cell Epitope," <u>Journal of Virology</u> , Vol. 65, No. 7, pp. 3641-3646, July 1991.			
	53	Tamashiro, J. C., et al., "Construction of a Cloned Library of the <i>EcoRI</i> Fragments from the Human Cytomegalovirus Genome (Strain AD169)," <u>Journal of Virology</u> , Vol. 42, No. 2, pp. 547-557, May 1982.			
	54	Clark, B. R., et al., "Isolation and Partial Chemical Characterization of a 64,000-Dalton Glycoprotein of Human Cytomegalovirus," <u>Journal of Virology</u> , Vol. 49, No. 1, pp. 279-282, January 1984.			
	55	Pande, H., et al., "Cloning and physical mapping of a gene fragment coding for a 64-kilodalton major late antigen of human cytomegalovirus," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 81, pp. 4965-4969, August 1984.			
	56	Riddell, S. R., et al., "Class I MHC-Restricted Cytotoxic T Lymphocyte Recognition of Cells Infected with Human Cytomegalovirus Does Not Require Endogenous Viral Gene Expression," <u>The Journal of Immunology</u> , Vol. 146, No. 8, pp. 2795-2804, April 15, 1991.			
	57	Spector, S. A., "Transmission of Cytomegalovirus Among Infants in Hospital Documented by Restriction-Endonuclease-Digestion Analyses," <u>The Lancet</u> , pp. 378-381, February 19, 1983.			
	58	Kern, F., et al., "Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides," <u>Eur. J. Immunol.</u> , Vol. 30, pp. 1676-1682, 2000.			
	59	Pachl, C., et al., "The Human Cytomegalovirus Strain Towne Glycoprotein H Gene Encodes Glycoprotein p86," <u>Virology</u> , Vol. 169, pp. 418-426, 1989.			
	60	Spaete, R. R., et al., "Human Cytomegalovirus Strain Towne Glycoprotein B Is Processed by Proteolytic Cleavage," <u>Virology</u> , Vol. 167, pp. 207-225, 1988.			
		61			
Examiner Signature				Date Considered	11/7/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.